BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23640178)

  • 1. Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A
    JAMA Ophthalmol; 2013 Jul; 131(7):923-4. PubMed ID: 23640178
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
    Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
    Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
    Sheth S; Rush R; Natarajan S; Gillies M
    Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intravitreal triamcinolone in diabetic macular edema unresponsive to intravitreal bevacizumab.
    Jeon S; Lee WK
    Retina; 2014 Aug; 34(8):1606-11. PubMed ID: 24553409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
    Lim JW; Lee HK; Shin MC
    Ophthalmologica; 2012; 227(2):100-6. PubMed ID: 21997197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema?
    Biester S; Ziemssen F; Ulrich Bartz-Schmidt K; Gelisken F
    Graefes Arch Clin Exp Ophthalmol; 2009 Nov; 247(11):1575-7. PubMed ID: 19582472
    [No Abstract]   [Full Text] [Related]  

  • 10. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
    Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
    Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The article by Kook et al 1 on the 1-year effect of bevacizumab in patients with chronic diffuse diabetic macular edema (DME).
    Querques G
    Retina; 2009 May; 29(5):718-9; author reply 719-20. PubMed ID: 19430285
    [No Abstract]   [Full Text] [Related]  

  • 13. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
    Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
    Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study.
    Bonini-Filho M; Costa RA; Calucci D; Jorge R; Melo LA; Scott IU
    Am J Ophthalmol; 2009 Jun; 147(6):1022-30, 1030.e1-5. PubMed ID: 19327746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
    Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
    Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
    Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema.
    Solaiman KA; Diab MM; Dabour SA
    Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
    Rajendram R; Fraser-Bell S; Kaines A; Michaelides M; Hamilton RD; Esposti SD; Peto T; Egan C; Bunce C; Leslie RD; Hykin PG
    Arch Ophthalmol; 2012 Aug; 130(8):972-9. PubMed ID: 22491395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of diabetic retinopathy with intravitreal Ranibizumab.
    Kernt M; Cserhati S; Seidensticker F; Liegl R; Kampik A; Neubauer A; Ulbig MW; Reznicek L
    Diabetes Res Clin Pract; 2013 Apr; 100(1):e11-3. PubMed ID: 23391744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
    Takamura Y; Kubo E; Akagi Y
    Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.